Senescence and immortality in hepatocellular carcinoma

Cancer Letters

Volumn 286, Issue 1, 2009, Pages 103-113

  Ozturk, Mehmet ^a,b   Arslan Ergul, Ayca ^a   Bagislar, Sevgi ^a,b   Senturk, Serif ^a   Yuzugullu, Haluk ^a,b  

^a BILKENT UNIVERSITY   (Turkey)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

Cirrhosis; DNA damage; Hepatocytes; Liver cancer; p16INK4a; p21Cip1; p53; Retinoblastoma; Senescence; Telomerase reverse transcriptase; Telomeres

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ATM PROTEIN; ATR PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; ONCOPROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RETINOBLASTOMA PROTEIN; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TRANSCRIPTION FACTOR E2F;

CANCER CELL; CELL AGING; CELL CYCLE ARREST; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRUCTURE; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; GENE ACTIVATION; GENE MUTATION; GENE SILENCING; GROWTH INHIBITION; HETEROCHROMATIN; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CELL CULTURE; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TELOMERE;

EID: 70350568297     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.048     Document Type: Review

References (91)

1. In: Crew D.E. (Ed). Human senescence-evolutionary and biocultural perspectives (2003), Cambridge University Press, Cambridge
2. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37 (1965) 614-636
3. Campisi J., and d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8 (2007) 729-740
4. Rudolph K.L., Chang S., Lee H.W., Blasco M., Gottlieb G.J., Greider C., and DePinho R.A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96 (1999) 701-712
5. Michalopoulos G.K. Liver regeneration. J. Cell Physiol. 213 (2007) 286-300
6. Paradis V., Youssef N., Dargere D., Ba N., Bonvoust F., Deschatrette J., and Bedossa P. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum. Pathol. 32 (2001) 327-332
7. Wiemann S.U., Satyanarayana A., Tsahuridu M., Tillmann H.L., Zender L., Klempnauer J., Flemming P., Franco S., Blasco M.A., Manns M.P., and Rudolph K.L. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 16 (2002) 935-942
8. Trak-Smayra V., Contreras J., Dondero F., Durand F., Dubois S., Sommacale D., Marcellin P., Belghiti J., Degott C., and Paradis V. Role of replicative senescence in the progression of fibrosis in hepatitis C virus (HCV) recurrence after liver transplantation. Transplantation 77 (2004) 1755-1760
9. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
10. Rudolph K.L., Chang S., Millard M., Schreiber-Agus N., and DePinho R.A. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 287 (2000) 1253-1258
11. Satyanarayana A., Wiemann S.U., Buer J., Lauber J., Dittmar K.E., Wüstefeld T., Blasco M.A., Manns M.P., and Rudolph K.L. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 22 (2003) 4003-4013
12. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
13. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19 (2005) 2100-2110
14. Blackburn E.H. Structure and function of telomeres, Nature 350 (1991) 569-573
15. Cong Y.S., Wright W.E., and Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 66 (2002) 407-425
16. Karlseder J., Smogorzewska A., and de Lange T. Senescence induced by altered telomere state. Not telomere loss, Science 295 (2002) 2446-2449
17. Verdun R.E., and Karlseder J. Replication and protection of telomeres, Nature 447 (2007) 924-931
18. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., and Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (2003) 194-198
19. Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
20. Di Micco R., Fumagalli M., and di Fagagna d.F. Breaking news: high-speed race ends in arrest-how oncogenes induce senescence. Trends Cell Biol. 17 (2007) 529-536
21. Mooi W.J., and Peeper D.S. Oncogene-induced cell senescence-halting on the road to cancer. N. Engl. J. Med. 355 (2006) 1037-1046
22. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., and Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725-730
23. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., Maestro R., Pelicci P.G., and d'Adda di Fagagna F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444 (2006) 638-642
24. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Ørntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., and Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444 (2006) 633-637
25. Lu T., and Finkel T. Free radicals and senescence. Exp. Cell Res. 314 (2008) 1918-1922
26. Giorgio M., Trinei M., Migliaccio E., and Pelicci P.G. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals?. Nat. Rev. Mol. Cell Biol. 8 (2007) 722-728
27. Blanchetot C., and Boonstra J. The ROS-NOX connection in cancer and angiogenesis. Crit. Rev. Eukaryot. Gene Expr. 18 (2008) 35-45
28. von Zglinicki T., Saretzki G., Döcke W., and Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence?. Exp. Cell Res. 220 (1995) 186-193
29. Lee A.C., Fenster B.E., Ito H., Takeda K., Bae N.S., Hirai T., Yu Z.X., Ferrans V.J., Howard B.H., and Finkel T. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem. 274 (1999) 7936-7940
30. Courtois-Cox S., Jones S.L., and Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 27 (2008) 2801-2809
31. Passos J.F., Saretzki G., Ahmed S., Nelson G., Richter T., Peters H., Wappler I., Birket M.J., Harold G., Schaeuble K., Birch-Machin M.A., Kirkwood T.B., and von Zglinicki T. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol. 5 (2007) e110
32. Ito K., Hirao A., Arai F., Takubo K., Matsuoka S., Miyamoto K., Ohmura M., Naka K., Hosokawa K., Ikeda Y., and Suda T. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12 (2006) 446-451
33. Herbig U., Jobling W.A., Chen B.P., Chen D.J., and Sedivy J.M. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a) but not p16(INK4a). Mol. Cell. 14 (2004) 501-513
34. Mallette F.A., Gaumont-Leclerc M.F., and Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 21 (2007) 43-48
35. Gil J., and Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7 (2006) 667-677
36. Alcorta D.A., Xiong Y., Phelps D., Hannon G., Beach D., and Barrett J.C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. U S A 93 (1996) 13742-13747
37. Zindy F., Quelle D.E., Roussel M.F., and Sherr C.J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15 (1997) 203-211
38. Tremain R., Marko M., Kinnimulki V., Ueno H., Bottinger E., and Glick A. Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene 19 (2000) 1698-1709
39. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., and Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132 (2008) 363-374
40. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., Takatsu Y., Melamed J., d'Adda di Fagagna F., Bernard D., Hernando E., and Gil J. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 (2008) 1006-1018
41. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., and Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008) 1019-1031
42. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
43. Deng Y., Chan S.S., and Chang S. Telomere dysfunction and tumor suppression: the senescence connection. Nat. Rev. Cancer 8 (2008) 450-458
44. Fang L., Igarashi M., Leung J., Sugrue M.M., Lee S.W., and Aaronson S.A. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18 (1999) 2789-2797
45. Giacinti C., and Giordano A. RB and cell cycle progression. Oncogene 25 (2006) 5220-5227
46. Narita M., Nunez S., Heard E., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., and Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113 (2003) 703-716
47. Zhang R., Poustovoitov M.V., Ye X., Santos H.A., Chen W., Daganzo S.M., Erzberger J.P., Serebriiskii I.G., Canutescu A.A., Dunbrack R.L., Pehrson J.R., Berger J.M., Kaufman P.D., and Adams P.D. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev. Cell 8 (2005) 19-30
48. Narita M., Narita M., Krizhanovsky V., Nunez S., Chicas A., Hearn S.A., Myers M.P., and Lowe S.W. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126 (2006) 503-514
49. Adams P.D. Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene 397 (2007) 84-93
50. Takubo K., Izumiyama-Shimomura N., Honma N., Sawabe M., Arai T., Kato M., Oshimura M., and Nakamura K. Telomere lengths are characteristic in each human individual. Exp. Gerontol. 37 (2002) 523-531
51. Aikata H., Takaishi H., Kawakami Y., Takahashi S., Kitamoto M., Nakanishi T., Nakamura Y., Shimamoto F., Kajiyama G., and Ide T. Telomere reduction in human liver tissues with age and chronic inflammation. Exp. Cell Res. 256 (2000) 578-582
52. Utoh R., Tateno C., Yamasaki C., Hiraga N., Kataoka M., Shimada T., Chayama K., and Yoshizato K. Susceptibility of chimeric mice with livers repopulated by serially subcultured human hepatocytes to hepatitis B virus. Hepatology 47 (2008) 435-446
53. Delhaye M., Louis H., Degraef C., Le Moine O., Devière J., Gulbis B., Jacobovitz D., Adler M., and Galand P. Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. Hepatology 23 (1996) 1003-1011
54. Stampfer M.R., and Yaswen P. Human epithelial cell immortalization as a step in carcinogenesis. Cancer Lett. 194 (2003) 199-208
55. Wege H., Le H.T., Chui M.S., Lui L., Wu J., Giri G., Malhi H., Sappal B.S., Kumaran V., Gupta S., and Zern M.A. Telomerase reconstitution immortalized human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 124 (2003) 432-444
56. Lechel A., Satyanarayana A., Ju Z., Plentz R.R., Schaetzlein S., Rudolph C., Wilkens L., Wiemann S.U., Saretzki G., Malek N.P., Manns M.P., Buer J., and Rudolph K.L. The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. EMBO Rep. 6 (2005) 275-281
57. Lazzerini Denchi E., Celli G., and de Lange T. Hepatocytes with extensive telomere deprotection and fusion remain viable and regenerate liver mass through endoreduplication. Genes Dev. 20 (2006) 2648-2653
58. Szabo G., Mandrekar P., and Dolganiuc A. Innate immune response and hepatic inflammation. Semin. Liver Dis. 27 (2007) 339-350
59. Malhi H., and Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 134 (2008) 1641-1654
60. Schuppan D., and Afdhal N.H. Liver cirrhosis. Lancet 371 (2008) 838-851
61. Farinati F., Cardin R., Bortolami M., Burra P., Russo F.P., Rugge M., Guido M., Sergio A., and Naccarato R. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J. Viral Hepat. 14 (2007) 821-829
62. Reuben A. Alcohol and the liver. Curr. Opin. Gastroenterol. 24 (2008) 328-338
63. Shimoda R., Nagashima M., Sakamoto M., Yamaguchi N., Hirohashi S., Yokota J., and Kasai H. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res. 54 (1994) 3171-3172
64. Zindy P., Andrieux L., Bonnier D., Musso O., Langouët S., Campion J.P., Turlin B., Clément B., and Théret N. Upregulation of DNA repair genes in active cirrhosis associated with hepatocellular carcinoma. FEBS Lett. 579 (2005) 95-99
65. Plentz R.R., Park Y.N., Lechel A., Kim H., Nellessen F., Langkopf B.H., Wilkens L., Destro A., Fiamengo B., Manns M.P., Roncalli M., and Rudolph K.L. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 45 (2007) 968-976
66. Roncalli M., Bianchi P., Bruni B., Laghi L., Destro A., Di Gioia S., Gennari L., Tommasini M., Malesci A., and Coggi G. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 36 (2002) 427-432
67. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin. Liver Dis. 19 (1999) 235-242
68. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 26 (2007) 2145-2156
69. Edamoto Y., Hara A., Biernat W., Terracciano L., Cathamos G., Riehle H.M., Matsuda M., Fuji H., Scoazec J.M., and Ohgaki H. Alterations of RB1, p53 and Wnt pathways in Hepatocellular carcinomas associated with HCV, HBV and alcoholic liver cirrhosis. Int. J. Cancer 106 (2003) 334-341
70. Tahara H., Nakanishi T., Kitamoto M., Nakashio R., Shay J.W., Tahara E., Kajiyama G., and Ide T. Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res. 55 (1995) 2734-2736
71. Kojima H., Yokosuka O., Imazeki F., Saisho H., and Omata M. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 112 (1997) 493-500
72. Nakayama J., Tahara H., Tahara E., Saito M., Ito K., Nakamura H., Nakanishi T., Tahara E., Ide T., and Ishikawa F. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet. 18 (1998) 65-68
73. Gozuacik D., Murakami Y., Saigo K., Chami M., Mugnier C., Lagorce D., Okanoue T., Urashima T., Bréchot C., and Paterlini-Bréchot P. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 20 (2001) 6233-6240
74. Horikawa I., and Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24 (2003) 1167-1176
75. Murakami Y., Saigo K., Takashima H., Minami M., Okanoue T., Bréchot C., and Paterlini-Bréchot P. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54 (2005) 1162-1168
76. Qu Z.L., Zou S.Q., Cui N.Q., Wu X.Z., Qin M.F., Kong D., and Zhou Z.L. Upregulation of human telomerase reverse transcriptase mRNA expression by in vitro transfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells. World J. Gastroenterol. 11 (2005) 5627-5632
77. Liu H., Luan F., Ju Y., Shen H., Gao L., Wang X., Liu S., Zhang L., Sun W., and Ma C. In vitro transfection of the hepatitis B virus PreS2 gene into the human hepatocarcinoma cell line HepG2 induces upregulation of human telomerase reverse transcriptase. Biochem. Biophys. Res. Commun. 355 (2007) 379-384
78. Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett. 564 (2004) 9-13
79. Miura N., Horikawa I., Nishimoto A., Ohmura H., Ito H., Hirohashi S., Shay J.W., and Oshimura M. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet. 93 (1997) 56-62
80. Lee J.E., Oh B.K., Choi J., and Park Y.N. Telomeric 3' overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma. Int. J. Cancer 123 (2008) 264-272
81. Oh B.K., Kim Y.J., Park C., and Park Y.N. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am. J. Pathol. 166 (2005) 73-80
82. Satyanarayana A., Manns M.P., and Rudolph K.L. Telomeres and Telomerase: a Dual role in hepatocarcinogenesis. Hepatology 40 (2004) 276-283
83. Lechel A., Holstege H., Begus Y., Schienke A., Kamino K., Lehmann U., Kubicka S., Schirmacher P., Jonkers J., and Rudolph K.L. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 132 (2007) 1465-1475
84. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumor cells with defined genetic elements. Nature 400 (1999) 464-468
85. Shay J.W., and Roninson I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23 (2004) 2919-2933
86. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguría A., Zaballos A., Flores J.M., Barbacid M., Beach D., and Serrano M. Tumour biology: senescence in premalignant tumours. Nature 436 (2005) 642
87. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dörken B., Jenuwein T., and Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005) 660-665
88. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., and Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
89. Suh S.I., Pyun H.Y., Cho J.W., Baek W.K., Park J.B., Kwon T., Park J.W., Suh M.H., and Carson D.A. 5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16 RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Lett. 160 (2000) 81-88
90. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., and Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. USA 104 (2007) 13028-13033
91. Ozturk N., Erdal E., Mumcuoglu M., Akcali K.C., Yalcin O., Senturk S., Arslan-Ergul A., Gur B., Yulug I., Cetin-Atalay R., Yakicier C., Yagci T., Tez M., and Ozturk M. Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. Proc. Natl. Acad. Sci. USA 103 (2006) 2178-2183